Impact of Germline BRCA Mutation Status on Antitumor Activity of Modified FOLFIRINOX in Patients With Advanced Pancreatic Cancer: An Exploratory Analysis
JCO Precision Oncology · 2026-03 · 10 (3)
DOI: 10.1200/po-25-01104 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JCO Precision Oncology, 2026-03. Verfasst von Lingaku Lee und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepato-Biliary-Pancreatology, NHO Kyushu Cancer Center, Fukuoka, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Pancreatic Neoplasms, Germ-Line Mutation, BRCA2 Protein. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Germline BRCA (g BRCA ) mutations confer increased sensitivity to platinum-based chemotherapy and have been associated with improved survival across several malignancies. This study investigated the effect of g BRCA mutation status on the antitumor activity of modified fluorouracil, folinic acid, irinotecan, and oxaliplatin (FOLFIRINOX; mFFX) in patients with advanced pancreatic cancer (APC). METHODS This multicenter retrospective study was performed in 178 patients with histologically confirmed APC who received mFFX, comprising 17 g BRCA -positive and 161 g BRCA -negative individuals. Efficacy outcomes, including progression-free survival (PFS), objective response rate (ORR), and normalization rate of carbohydrate antigen 19-9 (CA19-9), were compared between groups using univariate and multivariate analyses. RESULTS Median PFS was significantly longer in g BRCA -positive than in g BRCA -negative patients (10.6 v 5.3 months, P = .005). Independent predictors of PFS included g BRCA mutation (hazard ratio [HR], 3.65), disease extent (HR, 2.34), and previous chemotherapy (HR, 1.66). g BRCA- positive patients demonstrated a significantly higher ORR (82% v 34%, odds ratio, 0.11, P < .001) and CA19-9 normalization rate (69% v 10%, P < 0.01). ORR was associated with g BRCA status (HR, 0.04), disease extent (HR, 0.11), and treatment history (HR, 0.27). Among 68 responders, sustained shrinkage of both primary and metastatic tumors and continued CA19-9 decline were observed during the first 6 months in g BRCA- positive patients, whereas responses in g BRCA -negative patients plateaued after 3 months. Subgroup analysis revealed that most patient subgroups demonstrated superior PFS and ORR in the g BRCA -positive cohort compared with those in the g BRCA -negative cohort. CONCLUSION g BRCA mutation status was strongly associated with enhanced radiologic and biological responses to mFFX in APC. Routine screening for g BRCA mutations may provide essential guidance in therapeutic decision making and substantially improve clinical outcomes in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hepato-Biliary-Pancreatology, NHO Kyushu Cancer Center, Fukuoka, Japan.
- Department of Hepato-Biliary-Pancreatic Medicine, Saiseikai Fukuoka General Hospital, Fukuoka, Japan.
- Department of Gastroenterology, NHO Fukuoka Higashi Medical Center, Fukuoka, Japan.
ORCID-Profile: Lingaku Lee, Takashi Fujiyama, Terumasa Hisano, Rie Sugimoto, Tetsuro Akashi, Masayuki Furukawa
Zitieren
APA
Lee, L., Tachibana, Y., Matsuo, S., Niina, Y., Fujiyama, T., Hisano, T., Sugimoto, R., Akashi, T., Ogoshi, K., & Furukawa, M. (2026). Impact of Germline BRCA Mutation Status on Antitumor Activity of Modified FOLFIRINOX in Patients With Advanced Pancreatic Cancer: An Exploratory Analysis. JCO Precision Oncology, 10(3). https://doi.org/10.1200/po-25-01104
Vancouver
Lee L, Tachibana Y, Matsuo S, Niina Y, Fujiyama T, Hisano T, et al. Impact of Germline BRCA Mutation Status on Antitumor Activity of Modified FOLFIRINOX in Patients With Advanced Pancreatic Cancer: An Exploratory Analysis. JCO Precision Oncology. 2026;10(3). doi:10.1200/po-25-01104
BibTeX
@article{Lee2026,
author = {Lee, Lingaku and Tachibana, Yuichi and Matsuo, Susumu and Niina, Yusuke and Fujiyama, Takashi and Hisano, Terumasa and Sugimoto, Rie and Akashi, Tetsuro and Ogoshi, Keiichiro and Furukawa, Masayuki},
title = {Impact of Germline BRCA Mutation Status on Antitumor Activity of Modified FOLFIRINOX in Patients With Advanced Pancreatic Cancer: An Exploratory Analysis},
journal = {JCO Precision Oncology},
year = {2026},
volume = {10},
number = {3},
doi = {10.1200/po-25-01104}
}
EUVIMED